Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.57 | -0.82 | 0.55 | -0.61 |
| FCF Yield | 11.96% | 3.63% | 5.06% | 17.20% |
| EV / EBITDA | 9.33 | 9.50 | 8.28 | 7.56 |
| Quality | ||||
| ROIC | 1.72% | 4.44% | 3.51% | 3.12% |
| Gross Margin | 65.51% | 66.43% | 69.11% | 68.99% |
| Cash Conversion Ratio | 9.80 | 4.97 | 3.08 | 4.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.39% | 6.11% | 7.99% | 2.74% |
| Free Cash Flow Growth | 263.47% | -31.40% | -63.35% | 21.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.41 | 3.83 | 3.00 | 2.95 |
| Interest Coverage | 2.49 | 201.49 | 4.19 | 3.76 |
| Efficiency | ||||
| Inventory Turnover | 1.30 | 1.18 | 1.26 | 1.30 |
| Cash Conversion Cycle | 267.72 | 286.63 | 260.99 | 257.84 |